Skip to main content

Web Exclusives

FDA Updates

Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma

FDA Updates

Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma

FDA Updates

Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma

FDA Updates

FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma

FDA Updates

Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation

Technology

Acceptance of Artificial Intelligence in Healthcare Is Making Inroads

Meeting Highlights

AVBCC 2021 Highlights

Using Value-Based Contracts to Manage Oncology Costs While Keeping Focus on the Patient

Acute Lymphoblastic Leukemia

Cytokine Release Syndrome Associated with Treatment for Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Treatment-Associated Neurotoxicity in Patients with Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia

Page 2 of 43
Results 11 - 20 of 425